Literature DB >> 24191056

Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention.

Hua Liu1, Paul Talalay.   

Abstract

Exemestane (6-methyleneandrosta-1,4-diene-3,17-dione) is a synthetic steroidal inhibitor of the aromatase reaction that catalyzes the terminal and rate-limiting step of the biosynthesis of estrogens. It is active clinically in preventing, delaying progression of, and treating mammary cancers, many of which are estrogen receptor-positive. A striking feature of the structure of exemestane is an extended system of conjugated Michael reaction functions, which is also characteristic of inducers of a broad network of chemoprotective genes regulated by the Keap1 (Kelch-like ECA-associated protein)/Nrf2 (nuclear factor E2-related factor 2)/ARE (antioxidant response element) signaling system. These genes are largely involved in xenobiotic metabolism and antioxidative and anti-inflammatory protection, as well as the synthesis and reduction of glutathione. We show here that exemestane transcriptionally activates NAD(P)H:quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO-1), typical chemoprotective gene products, in a wide variety of mouse, rat, and human cells. It protects several cell lines against oxidative toxicity of tert-butyl hydroperoxide and 4-hydroxynonenal, against free radical damage arising from hypoxia-reoxygenation, and against UVA radiation damage. Exemestane also inhibits the inflammatory increases in inducible nitric oxide synthase (iNOS) in mouse macrophages exposed to LPS (lipopolysaccharide), thereby resembling the isothiocyanate sulforaphane derived from broccoli. Remarkably, combinations of exemestane and sulforaphane act highly synergistically, and this property is also displayed by several other phytochemicals. Thus, exemestane has a wide range of previously unrecognized protective activities, probably unrelated to aromatase inhibition. Its potential for reducing the risk, not only of breast cancer, but also of other chronic diseases that arise from inflammation, oxidative stress, and DNA-damaging electrophiles, requires exploration, particularly in view of the synergism with other phytochemicals.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24191056      PMCID: PMC3839725          DOI: 10.1073/pnas.1318247110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Exemestane for breast-cancer prevention in postmenopausal women.

Authors:  Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson
Journal:  N Engl J Med       Date:  2011-06-04       Impact factor: 91.245

2.  "MAPping" the course of chemoprevention in breast cancer.

Authors:  Nancy E Davidson; Thomas W Kensler
Journal:  N Engl J Med       Date:  2011-06-04       Impact factor: 91.245

3.  Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer.

Authors:  Yuan Yao; Angela M H Brodie; Nancy E Davidson; Thomas W Kensler; Qun Zhou
Journal:  Breast Cancer Res Treat       Date:  2010-07-10       Impact factor: 4.872

Review 4.  NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.

Authors:  Albena T Dinkova-Kostova; Paul Talalay
Journal:  Arch Biochem Biophys       Date:  2010-03-31       Impact factor: 4.013

Review 5.  When NRF2 talks, who's listening?

Authors:  Nobunao Wakabayashi; Stephen L Slocum; John J Skoko; Soona Shin; Thomas W Kensler
Journal:  Antioxid Redox Signal       Date:  2010-07-09       Impact factor: 8.401

6.  An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1.

Authors:  Albena T Dinkova-Kostova; Paul Talalay; John Sharkey; Ying Zhang; W David Holtzclaw; Xiu Jun Wang; Emilie David; Katherine H Schiavoni; Stewart Finlayson; Dale F Mierke; Tadashi Honda
Journal:  J Biol Chem       Date:  2010-08-26       Impact factor: 5.157

7.  Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals.

Authors:  Michael McMahon; Douglas J Lamont; Kenneth A Beattie; John D Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

Review 8.  The cytoprotective role of the Keap1-Nrf2 pathway.

Authors:  Liam Baird; Albena T Dinkova-Kostova
Journal:  Arch Toxicol       Date:  2011-03-02       Impact factor: 5.153

Review 9.  Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.

Authors:  C Falandry; P A Canney; G Freyer; L Y Dirix
Journal:  Ann Oncol       Date:  2009-03-02       Impact factor: 32.976

Review 10.  Phytochemicals for breast cancer prevention by targeting aromatase.

Authors:  Lynn S Adams; Shiuan Chen
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  25 in total

1.  Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.

Authors:  Raju Khatri; Preeti Shah; Rupa Guha; Feyruz V Rassool; Alan E Tomkinson; Angela Brodie; Anil K Jaiswal
Journal:  Mol Cancer Ther       Date:  2015-05-14       Impact factor: 6.261

2.  Broccoli-Derived Nanoparticle Inhibits Mouse Colitis by Activating Dendritic Cell AMP-Activated Protein Kinase.

Authors:  Zhongbin Deng; Yuan Rong; Yun Teng; Jingyao Mu; Xiaoying Zhuang; Michael Tseng; Abhilash Samykutty; Lifeng Zhang; Jun Yan; Donald Miller; Jill Suttles; Huang-Ge Zhang
Journal:  Mol Ther       Date:  2017-03-06       Impact factor: 11.454

3.  Sulforaphane Ameliorates Limb Ischemia/Reperfusion-Induced Muscular Injury in Mice by Inhibiting Pyroptosis and Autophagy via the Nrf2-ARE Pathway.

Authors:  Huanhuan Sun; Jueqiong Wang; Wei Bi; Feng Zhang; Kui Chi; Long Shi; Tao Yuan; Kai Ma; Xiang Gao
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-11       Impact factor: 2.650

4.  Loss of Notch1-dependent p21(Waf1/Cip1) expression influences the Notch1 outcome in tumorigenesis.

Authors:  Samantha Cialfi; Rocco Palermo; Sonia Manca; Carlo De Blasio; Paula Vargas Romero; Saula Checquolo; Diana Bellavia; Daniela Uccelletti; Michele Saliola; Angelo D'Alessandro; Lello Zolla; Alberto Gulino; Isabella Screpanti; Claudio Talora
Journal:  Cell Cycle       Date:  2014-05-06       Impact factor: 4.534

5.  Metallothionein plays a prominent role in the prevention of diabetic nephropathy by sulforaphane via up-regulation of Nrf2.

Authors:  Hao Wu; Lili Kong; Yanli Cheng; Zhiguo Zhang; Yangwei Wang; Manyu Luo; Yi Tan; Xiangmei Chen; Lining Miao; Lu Cai
Journal:  Free Radic Biol Med       Date:  2015-09-28       Impact factor: 7.376

6.  Sexual Dimorphism in Response to an NRF2 Inducer in a Model for Pachyonychia Congenita.

Authors:  Michelle L Kerns; Jill M C Hakim; Abigail Zieman; Rosemary G Lu; Pierre A Coulombe
Journal:  J Invest Dermatol       Date:  2017-12-24       Impact factor: 8.551

Review 7.  Repurposing Drugs to Treat Heart and Brain Illness.

Authors:  Maranda S Cantrell; Alejandro Soto-Avellaneda; Jackson D Wall; Aaron D Ajeti; Brad E Morrison; Lisa R Warner; Owen M McDougal
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-16

8.  Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease.

Authors:  Barbara Nuvoli; Sabrina Germoni; Carlotta Morosetti; Raffaela Santoro; Giancarlo Cortese; Serena Masi; Iole Cordone; Rossella Galati
Journal:  Mol Cancer       Date:  2014-03-21       Impact factor: 27.401

Review 9.  Diet components can suppress inflammation and reduce cancer risk.

Authors:  W Elaine Hardman
Journal:  Nutr Res Pract       Date:  2014-05-15       Impact factor: 1.926

10.  Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1.

Authors:  Camilla Fusi; Serena Materazzi; Silvia Benemei; Elisabetta Coppi; Gabriela Trevisan; Ilaria M Marone; Daiana Minocci; Francesco De Logu; Tiziano Tuccinardi; Maria Rosaria Di Tommaso; Tommaso Susini; Gloriano Moneti; Giuseppe Pieraccini; Pierangelo Geppetti; Romina Nassini
Journal:  Nat Commun       Date:  2014-12-08       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.